LATEST VERSION
DEVELOPING · 9 NOV → 15 NOV 2026 · 7 EDITIONS · 51 OUTLETS

FDA orders vision-loss risk warnings for GLP-1 drugs

How this story moved: how many newsrooms carried it at each run, when each one picked it up, how our summary's headline changed, and which figures and names held from the first reports to the latest. Everything here is counted from the coverage; none of it is a judgement of anyone's motives.

OUTLETS CARRYING THE STORY, RUN BY RUN

0 25 51 10 Nov 11 Nov 12 Nov 13 Nov 14 Nov 15 Nov 10 Nov 00:19 UTC · US FDA orders new eye risk warnings for Ozempic, Zepbound 10 Nov 06:14 UTC · US FDA orders new eye risk warnings for Ozempic, Zepbound 10 Nov 18:17 UTC · US FDA orders new eye risk warnings for Ozempic, Zepbound 11 Nov 00:15 UTC · US FDA orders new eye risk warnings for Ozempic, Zepbound 11 Nov 12:16 UTC · FDA orders vision-loss risk warning for GLP-1 drugs 12 Nov 18:29 UTC · FDA orders vision-loss risk warnings for GLP-1 drugs

HOW OUR HEADLINE CHANGED · 3 HEADLINES

  1. 11 Nov, 00:15 UTC

    US FDA orders new eye risk warnings for Ozempic, Zepbound

  2. 11 Nov, 12:16 UTC

    FDA orders vision-loss risk warning for GLP-1 drugs

  3. 12 Nov, 18:29 UTC

    FDA orders vision-loss risk warnings for GLP-1 drugs

WHAT HELD, WHAT CAME LATER

From the first reports to the latest

  • Novo Nordisk · 3 outlets
  • Eli Lilly · 2 outlets

Entered the story later

  • 126 clinical trials · from 11 Nov 08:45, 2 outlets
  • 100,000 person-years among · from 11 Nov 08:45, 2 outlets
  • 100,000 people followed · from 11 Nov 08:45, 2 outlets

Figures reported with different numbers

  • people followed: 100,000 (2 from 11 Nov 08:45) → 50,000 (1 from 11 Nov 08:45)

Matched by pattern, not read: a different number can be a correction, a rising count, or two different counts.